Best of ASCO - 2014 Annual Meeting



Ovarian Cancer

Gynecologic Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
BRCA1/BRCA2 mutations behavior and clinical evaluation in Mexican ovarian cancer patients.

Dolores Gallardo-Rincon


53BP1 as a predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Rachel M Hurley


A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.

Alexandra Leary


A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.

Joshua Millstein


A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trial—A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.

Jose Alejandro Perez-Fidalgo


A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).

Joyce F. Liu


A phase I dose-escalation of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin for the frontline treatment of advanced ovarian cancer.

Leslie M. Randall


A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.

Roisin Eilish O'Cearbhaill


A phase Ib trial of pembrolizumab (Pembro) following adoptive cell therapy (ACT) in patients with platinum-resistant ovarian cancer; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) trial.

Josee-Lyne Ethier


A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.

Robert L. Coleman


AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.

Ignace Vergote


An open-label phase 1 trial of the safety and efficacy of daily subcutaneous SPL-108 injections when used in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer.

Eugenia Girda


Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: A single-arm, open-label, phase 2 study.

Chunyan Lan


Assessing delay and barriers to risk-reducing surgery in women with BRCA mutations.

Anne Olsen


Association of diabetes mellitus with an increased risk of recurrence and disease progression in women with ovarian granulosa cell tumors.

Joan Tymon-Rosario


Association of high tumor mutation (TMB) with DNA damage repair (DDR) alterations and better prognosis in ovarian cancer.

Wenjuan Tian


Association of unplanned hospitalizations after chemotherapy with disease specific survival in a racially ethnically diverse population of women with epithelial ovarian cancer.

Shayan M Dioun


ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.

Jean Emmanuel Kurtz


Bioanalysis of samples from advanced ovarian cancer subjects treated with a combination of DPX-Survivac, metronomic cyclophosphamide, and epacadostat: Preliminary data from the phase Ib DeCidE1 Trial.

Olga Hrytsenko


Can serum IL-6 be a sentinel biomarker of cancer cachexia in gynecologic cancer patients?

Tomoyuki Yoshikwa


Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.

Michael Friedlander


Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

Sandro Pignata


Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease.

Michael-John Devlin


Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.

Oliver Dorigo


Clinical impact of BRCA1 and BRCA2 mRNA expression in ovarian cancer.

Irina Tsibulak


Clinical relevance of Vav3.1 expression in ovarian cancer and involvement in mechanisms causing genuine multi-drug resistance.

Daniel Uwe Reimer


Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Richard T. Penson


Combination of triapine, olaparib, and cediranib for epithelial ovarian cancer therapy.

Z Ping Lin


Combinatorial inhibition of Polo-like kinase 1 (PLK1) and microtubule dynamics to induce synthetic lethality in ovarian cancer cells with CCNE1-amplification.

Sven Becker


Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.

Tharani Sivakumaran


Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602.

Takashi ONDA


Comprehensive analysis of genomic alterations in Chinese high-grade serous ovarian carcinoma patients.

Fangfang Zhong


Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.

Megan Buechel


Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.

Juliet Elizabeth Wolford


Cost-effectiveness of niraparib versus routine surveillance, olaparib, and rucaparib for the maintenance treatment of adult patients with ovarian cancer in the United States.

Mark Fisher


CUDC-907, a dual HDAC and PI3K inhibitor, to inhibit cancer progression both in high and low grade ovarian carcinoma cell lines.

Marufa Rumman


Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.

Lukas Rob


Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.

David Cibula


Determinants of severe chronic fatigue among epithelial ovarian cancer survivors: A GINECO VIVROVAIRE study.

Florence Joly


Differences in survival between Caucasians and Asians.

John K. Chan


EDMONd: A feasibility study of elemental diet as an alternative to parenteral nutrition for ovarian cancer patients with inoperable malignant bowel obstruction.

Agnieszka Michael


Effect of adjuvant therapy for stage II and III ovarian cancer in patients older than 70 years.

Samip R. Master


Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.

Robert Armbrust


Efficacy and immune modulation of the tumor microenvironment with the combination of the PARP inhibitor rucaparib and CD122-biased agonist NKTR-214.

Andrew Simmons


Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.

Carol Aghajanian


Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.

Ana Oaknin


Exploring ovarian cancer detection using an interdisciplinary investigation of its volatile odor signature.

Lorenzo Ramirez


Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: Uptake of genetic assessment and testing and impact on patient-reported stress, anxiety and depression.

Sarah S. Lee


Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.

Robert Allen Burger


First results of a prospective national controlled study: Prophylactic Radical Fimbriectomy (NCT01608074), in women with a hereditary familial risk of breast/ovarian cancer—Tolerance and pathological findings.

Eric Leblanc


Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC).

Elena Ioana Braicu


Genomic mutation profiles of paired ovarian cancers (OC) across time.

Julia Fehniger


Histone deacetylase inhibition alters tumor phenotype and stimulates a productive anti-tumor immune response in preclinical models of ovarian cancer.

Tyler McCaw


Identification of outcome-correlated serum cytokine and chemokine clusters in ovarian clear cell carcinoma.

Akira Yabuno


Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.

Jacob Korach


Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced ovarian cancer.

Julia Salinaro


Incidence of venous thromboembolism in the gynecologic cancer patient population at a single institution after implementation of pre-operative venous thromboembolism prophylaxis.

Elizabeth Hopp


Inhibition of the Wnt/β-catenin pathway to promote T-cell immunity and survival in a syngeneic mouse model of ovarian cancer.

David W Doo


INNOVATE-3: Phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer.

Eilon David Kirson


Integrated molecular analysis of Asian ovarian cancer: Gene expression and whole exome sequencing analyses from the iPocc Translational Research study (TriPocc).

Ruby Huang


Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.

Michelle K. Wilson


Interval between last neoadjuvant chemotherapy and surgery and between surgery and first adjuvant chemotherapy in ovarian cancer patients.

Alexandre Andre B. A. Da Costa


LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study.

Annette Hasenburg


Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.

Kirsten Timms


Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.

Karina Dahl Steffensen


METRO-BIBF: Phase II, randomised, placebo controlled, multicentre, trial of low dose (metronomic) cyclophosphamide (MCy) with or without nintedanib in relapsed ovarian cancer (ROC).

Marcia Hall


Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.

David M. O'Malley


Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.

Min Wang


Nanoparticle micellar formulation of paclitaxel in combination with carboplatin for women with recurrent platinum sensitive ovarian cancer (OAS07-OVA): Overall survival results of a phase 3 randomized trial.

Nina Heldring


Novel orally bioavailable tubulin inhibitor VERU-111 to suppress ovarian tumor growth and metastasis.

Guannan Zhao


Olaparib in German routine clinical practice: Updated interim results of the non-interventional study C-PATROL.

Frederik Marme


Olaparib-induced severe folate deficiency in women with relapsed ovarian cancer: First report and case series.

Jamile M. Shammo


Outcome of patients undergoing delayed debulking surgery (DDS) in advanced ovarian cancer (OC).

Shanthini M Crusz


OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer following response on frontline platinum-based chemotherapy.

Joanie M. Hope


Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial.

Li Li


Paired somatic and germline genetic testing for ovarian cancer patients: Observations, benefits and implications for treatment.

Daniel Chen


PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.

Susana N. Banerjee


PD-1 inhibitor treatment of platinum-resistant epithelial ovarian cancer.

Jan Oldenburg


PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

Jasgit C. Sachdev


Phase 1b study of oncolytic vaccinia virus GL-ONC1 in recurrent ovarian cancer (ROC).

Robert W. Holloway


Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).

Lainie P. Martin


Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Iurie Bulat


Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Nicole Concin


Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.

William Rayford Gwin


Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study.

Chyong-Huey Lai


Phylogenetic characteristics as a potential prognostic factor in serous ovarian cancer.

Qin Zhang


Platinum based chemotherapy selects for PDGFRα dependent angiogenesis.

Nuala McCabe


Potential impact of dietary intervention/counseling on survival in ovarian cancer patients: Results from an observational study.

Jessica Michalak


Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial.

Florian Heitz


Predictive factors for prolonged response to olaparib as maintenance therapy in ovarian cancer patients with BRCA mutations.

Sana Intidhar Labidi-Galy


PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.

Charlie Gourley


Prognostic relevance of supradiaphragmatic lymph nodes in advanced stage ovarian cancer.

Daniel Uwe Reimer


Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.

Xavier Paoletti


QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

Kathleen N. Moore


Real-world Effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA) : A Korean Gynecologic Oncology Group study (KGOG 3041).

Jung-Yun Lee


Role of primary surgery for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer.

Philipp Harter


Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab.

Stefan Kommoss


Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).

Anna Fagotti


Survival and safety in patients with advanced ovarian cancer undergoing aggressive primary and interval debulking surgery.

Shinichi Tate


Survival impact of secondary cytoreductive surgery for platinum-sensitive relapsed serous ovarian cancer.

Jingjing Liu


The clinical outcome of FAP+ cancer-associated fibroblasts in high-grade serous ovarian cancer.

Hanna Dahlstrand


The impact of health related quality of life (HRQoL) on short term survival of recurrent ovarian cancer patients: Analysis of pooled data from the North-Eastern German Society of Gynecological Oncology (NOGGO) meta data base.

Jalid Sehouli


TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

Panagiotis A. Konstantinopoulos


Topotecan (T) + Pazopanib (P) in platinum-resistant or intermediate-sensitive ovarian cancer: a phase I/II single-arm multicentre trial of the North-Eastern German Society of Gynaecologic Oncology: TOPAZ.

Radoslav Chekerov


Toxicity profile of patients with gynecological cancers (Gyne) enrolled in phase I trials.

Yeh Chen Lee


Treating recurrent tuboovarian carcinoma with multiple lines of bevacizumab-based therapy: Feasibility and effectiveness in the clinical routine.

Christian M. Kurbacher


Treatment pattern differences across the United States and EU5 among patients with ovarian cancer.

Chitra Karki


Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.

Johanne I Weberpals


Tumor regression grading after neoadjuvant chemotherapy predicts long-term outcome of stage IIIC epithelial ovarian cancer.

Mingyi Zhou


Using GeneReader NGS system to identify mutations in BRCA 1/2 genes in matched FFPE and blood samples.

Vishal Kapoor


Utility of PETCT over conventional imaging in ovarian cancer.

Sarah Cook